Article
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2009
Bai Hua, Mao Li, Wang Hang Shu, Zhao Jun, Yang Lu, An Tong Tong, Wang Xin, Duan Chun Jian, Wu Na Mei, Guo Zhi Qing, Liu Yi Xu, Liu Hong Ning, Wang Ye Yu, Wang Jie
Abstract excerpt
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) kinase domain can predict tumor response to tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). However, obtaining tumor tissues for mutation analysis is challenging. We hypothesized that plasma-based EGFR mutation analysis is feasible and has value in predicting tumor response in patients with NSCLC. PATIENTS AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.